###begin article-title 0
AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
###end article-title 0
###begin p 1
###xml 30 45 30 45 <email xmlns:xlink="http://www.w3.org/1999/xlink">xjiang@bccrc.ca</email>
CORRESPONDENCE Xiaoyan Jiang: xjiang@bccrc.ca
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 430 461 430 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abelson helper integration site</italic>
###xml 465 477 465 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1)/AHI-1</italic>
###xml 570 577 570 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 653 664 653 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1/AHI-1</italic>
###xml 789 796 789 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 839 844 839 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 848 855 848 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 870 871 870 871 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 875 876 875 876 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1009 1014 1009 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 1018 1025 1018 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1084 1091 1084 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1498 1503 1498 1503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 668 674 <span type="species:ncbi:10090">murine</span>
###xml 679 684 <span type="species:ncbi:9606">human</span>
###xml 877 882 <span type="species:ncbi:9606">human</span>
Chronic myeloid leukemia (CML) represents the first human malignancy successfully treated with a tyrosine kinase inhibitor (TKI; imatinib). However, early relapses and the emergence of imatinib-resistant disease are problematic. Evidence suggests that imatinib and other inhibitors may not effectively eradicate leukemic stem/progenitor cells, and that combination therapy directed to complimentary targets may improve treatment. Abelson helper integration site 1 (Ahi-1)/AHI-1 is a novel oncogene that is highly deregulated in CML stem/progenitor cells where levels of BCR-ABL transcripts are also elevated. Here, we demonstrate that overexpression of Ahi-1/AHI-1 in murine and human hematopoietic cells confer growth advantages in vitro and induce leukemia in vivo, enhancing effects of BCR-ABL. Conversely, RNAi-mediated suppression of AHI-1 in BCR-ABL-transduced lin-CD34+ human cord blood cells and primary CML stem/progenitor cells reduces their growth autonomy in vitro. Interestingly, coexpression of Ahi-1 in BCR-ABL-inducible cells reverses growth deficiencies exhibited by BCR-ABL down-regulation and is associated with sustained phosphorylation of BCR-ABL and enhanced activation of JAK2-STAT5. Moreover, we identified an AHI-1-BCR-ABL-JAK2 interaction complex and found that modulation of AHI-1 expression regulates phosphorylation of BCR-ABL and JAK2-STAT5 in CML cells. Importantly, this complex mediates TKI response/resistance of CML stem/progenitor cells. These studies implicate AHI-1 as a potential therapeutic target downstream of BCR-ABL in CML.
###end p 3
###begin p 4
Abbreviations used: Ahi-1, Abelson helper integration site 1; BFU-E, burst-forming-units-erythroid; CB, cord blood; CFC, colony-forming cell; CFU-GEMM, colony-forming units-granulocyte-erythrocyte-monocyte-megakaryocyte; CFU-GM, colony-forming units-granulocyte-macrophage; CML, chronic myeloid leukemia; co-IP, coimmunoprecipitation; Dox, doxycycline; DS, dasatinib; GF, growth factor; IM, imatinib mesylate; IRES, internal ribosomal entry site; LTC-IC, long-term culture-initiating cell; NL, nilotinib; Q-RT-PCR, quantitative real-time-PCR; PI3K, phosphatidylinositol 3-kinase; SFM, serum-free medium; TKI, tyrosine kinase inhibitor.
###end p 4
###begin p 5
###xml 188 195 188 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 212 213 212 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 220 227 220 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 364 365 364 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 367 368 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 595 596 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 598 599 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 690 691 686 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 738 739 734 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 740 741 736 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 872 874 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 876 878 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 961 963 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 965 967 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 969 971 965 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 1009 1011 1005 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 1237 1239 1233 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 1241 1243 1237 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 1470 1472 1466 1468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 1473 1475 1469 1471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 1583 1585 1579 1581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 728 736 <span type="species:ncbi:9606">patients</span>
###xml 862 870 <span type="species:ncbi:9606">patients</span>
###xml 1201 1209 <span type="species:ncbi:9606">patients</span>
###xml 1324 1332 <span type="species:ncbi:9606">patients</span>
###xml 1865 1873 <span type="species:ncbi:9606">patients</span>
Chronic myeloid leukemia (CML) is a clonal, multistep, multilineage myeloproliferative disorder. It is initiated and propagated by a rare population of CML stem cells that have acquired a BCR-ABL fusion gene (1, 2). The BCR-ABL fusion gene encodes a chimeric oncoprotein that displays constitutively elevated tyrosine kinase activity that drives CML pathogenesis (3, 4). These features deregulate cellular proliferation and apoptosis control through effects on multiple intracellular signaling pathways, including the Ras, phosphatidylinositol 3-kinase (PI3K), JAK-STAT, and NF-kappaB pathways (5, 6). Recently, imatinib mesylate (IM), which is an inhibitor of the BCR-ABL tyrosine kinase (4), has shown promise in treating CML patients (7-9). However, early relapses and IM-resistant disease have emerged as significant clinical problems in some IM-treated CML patients (10, 11). Relapses are frequently associated with mutations in the BCR-ABL kinase domain (10, 12, 13), accounting for 60-90% of relapses (11). Dasatinib (DS) and nilotinib (NL) are more recently produced small molecule inhibitors of the BCR-ABL-encoded kinase with greater potencies than IM and predicted broader effectiveness in patients with IM-resistant disease (14, 15). Recent studies have indicated that CML stem/progenitor cells in chronic phase patients are less responsive to IM and other tyrosine kinase inhibitors (TKIs), and that they are a critical target population for IM resistance (16-18). In addition, CML stem cells are genetically unstable and rapidly generate IM-resistant mutants in vitro (19). Thus, it is critical to identify other therapies targeting CML stem/progenitor cells to prevent acquisition of resistance. There is also an emerging imperative to develop complementary therapies that target downstream molecular events in the CML stem/progenitor cells of those patients who fail to achieve lasting remission with current treatments.
###end p 5
###begin p 6
###xml 0 33 0 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Abelson helper integration site 1</italic>
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 203 208 203 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 581 587 581 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1)</italic>
###xml 666 671 666 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 728 733 728 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 805 807 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 809 811 809 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 844 855 844 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1/AHI-1</italic>
###xml 979 981 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 984 995 984 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1/AHI-1</italic>
###xml 1173 1178 1173 1178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1236 1238 1236 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 1240 1242 1240 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 1327 1328 1327 1328 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1336 1337 1336 1337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1373 1374 1373 1374 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1479 1486 1479 1486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1557 1559 1557 1559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 1561 1563 1561 1563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 131 136 <span type="species:ncbi:10090">mouse</span>
###xml 197 202 <span type="species:ncbi:10090">Mouse</span>
###xml 564 569 <span type="species:ncbi:9606">human</span>
###xml 774 779 <span type="species:ncbi:10090">mouse</span>
###xml 962 966 <span type="species:ncbi:10090">mice</span>
###xml 971 977 <span type="species:ncbi:9606">humans</span>
###xml 1209 1214 <span type="species:ncbi:9606">human</span>
###xml 1437 1445 <span type="species:ncbi:9606">patients</span>
Abelson helper integration site 1 (Ahi-1) is a novel gene that was identified by provirus insertional mutagenesis in v-abl-induced mouse pre-B cell lymphoma as a candidate cooperate oncogene (20). Mouse Ahi-1 encodes a unique protein with a SH3 domain, multiple SH3 binding sites, and a WD40-repeat domain, which are all known to be important mediators of protein-protein interactions, suggesting that the normal Ahi-1 protein has novel signaling activities and that its deregulation could affect specific cellular signaling pathways. Interestingly, the conserved human homologue (AHI-1) has an additional coiled-coil domain in its N-terminal region. Involvement of Ahi-1 in leukemogenesis is suggested by the high frequency of Ahi-1 mutations seen in certain virus-induced mouse leukemias and lymphomas (20, 21). We recently demonstrated that Ahi-1/AHI-1 expression is regulated at multiple stages of hematopoiesis in a fashion that is highly conserved between mice and humans (22). Ahi-1/AHI-1 is expressed at its highest level in the most primitive hematopoietic cells and is rapidly down-regulated as cells begin to differentiate. Interestingly, marked deregulation of AHI-1 expression is seen in several human leukemic cell lines (22, 23), particularly in a CML cell line (K562) and in Philadelphia chromosome-positive (Ph+ BCR-ABL+) primary leukemic cells, but not Ph- cells, especially in highly enriched leukemic stem cells from patients with CML. In addition, levels of BCR-ABL transcripts are highly elevated in the same CML stem cell population (18, 24), suggesting that it may be important to cooperative activities of AHI-1 and BCR-ABL to generate a permanently expanding clone of deregulated stem cells at the early stage of leukemia development.
###end p 6
###begin p 7
###xml 53 64 53 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1/AHI-1</italic>
###xml 101 108 101 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 292 297 292 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 449 456 449 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 480 485 480 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 514 521 514 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1043 1044 1043 1044 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1061 1072 1061 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1/AHI-1</italic>
###xml 152 157 <span type="species:ncbi:10090">mouse</span>
###xml 162 167 <span type="species:ncbi:9606">human</span>
###xml 543 548 <span type="species:ncbi:9606">human</span>
###xml 609 617 <span type="species:ncbi:9606">patients</span>
In this study, biological and molecular functions of Ahi-1/AHI-1 and its cooperative activities with BCR-ABL were extensively investigated in primitive mouse and human hematopoietic cells using several overexpression, suppression, and inducible model systems. We found that overexpression of Ahi-1 alone in primitive hematopoietic cells confers a proliferative advantage in vitro and induces a lethal leukemia in vivo; these effects are enhanced by BCR-ABL. Stable suppression of AHI-1 by small interfering RNA in BCR-ABL-transduced primitive human cord blood (CB) cells and primitive leukemic cells from CML patients reduces their growth autonomy in vitro. The regulatory role of Ahi-1/AHI-1 in mediating BCR-ABL transforming activities can be further explained by demonstration of a direct physical interaction between AHI-1 and BCR-ABL at endogenous levels in CML cells. This is associated with JAK2 and results in modulation of sensitivity to TKIs and differing levels of BCR-ABL tyrosine phosphorylation and JAK2-STAT5 activity in BCR-ABL+ CML cells where Ahi-1/AHI-1 expression is either coexpressed or inhibited.
###end p 7
###begin title 8
RESULTS
###end title 8
###begin title 9
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 129 136 129 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
Overexpression of Ahi-1 alone can transform IL-3-dependent BaF3 cells in vitro and in vivo, and these effects can be enhanced by BCR-ABL
###end title 9
###begin p 10
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 97 102 97 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 296 301 296 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 346 351 346 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 441 446 441 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 622 627 622 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 819 824 819 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 829 836 829 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 932 939 932 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 943 948 943 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 1174 1181 1174 1181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</sup>
###xml 1231 1236 1231 1236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 1241 1248 1241 1248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1264 1271 1264 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
To investigate the transforming potential of Ahi-1 in hematopoietic cells, we cloned full-length Ahi-1 cDNA into a MSCV-internal ribosomal entry site (IRES)-YFP (MIY) vector and overexpressed it in an IL-3-dependent cell line (BaF3). Quantitative real-time RT-PCR analysis (Q-RT-PCR) showed that Ahi-1 transcript levels were greatly increased in Ahi-1-transduced BaF3 clonal cell lines compared with control cells (Fig. S1 A available at ). Ahi-1-transduced cells have increased proliferative activity in the presence of IL-3, and this effect was markedly enhanced when IL-3 was not added (3-4-fold; P < 0.01; Fig. S1 C). Ahi-1-transduced cells also had greater cell viability in the presence of a low concentration of IL-3 (2 ng/ml) compared with control cells (twofold; Fig. S1 D). Interestingly, overexpressing both Ahi-1 and BCR-ABL in BaF3 cells further enhanced these perturbations, compared with cells transduced with either BCR-ABL or Ahi-1 alone (1.5-3.5-fold in the absence or presence of IL-3; P < 0.05; Fig. S1, C and D). Western blot analysis of protein from two individual clonal lines revealed that both protein expression and tyrosine kinase activity of p210BCR-ABL were highly increased in cells cotransduced with Ahi-1 and BCR-ABL, compared with BCR-ABL-transduced cells (Fig. S1 E). We also detected higher levels of Ahi-1 protein expression in the same dually transduced cells than in those transduced with Ahi-1 alone. More interestingly, endogenous Ahi-1 expression is increased in cells transduced with BCR-ABL alone compared with control cells with expression levels being similar to those detected in Ahi-1-transduced BaF3 cells (Fig. S1 E).
###end p 10
###begin p 11
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 208 211 202 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 263 268 257 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 332 333 326 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 351 359 345 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 405 412 399 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 513 518 507 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 523 530 517 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 577 585 571 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 733 738 727 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 742 749 736 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 826 827 820 821 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 833 834 827 828 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 839 840 833 834 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 848 849 842 843 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 862 863 856 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 866 867 860 861 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 903 911 897 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 994 999 988 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 1004 1011 998 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1030 1038 1024 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 1043 1050 1037 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table I</xref>
###xml 1181 1186 1175 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 1271 1272 1265 1266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1277 1278 1271 1272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1296 1297 1290 1291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1315 1316 1309 1310 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1337 1338 1331 1332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1341 1342 1335 1336 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1355 1363 1349 1357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 1400 1405 1394 1399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 1538 1543 1532 1537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 1548 1555 1542 1549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1592 1593 1586 1587 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1599 1600 1593 1594 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1607 1608 1601 1602 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1616 1617 1610 1611 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1869 1874 1863 1868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 2015 2022 2009 2016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 212 216 <span type="species:ncbi:10090">mice</span>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 344 349 <span type="species:ncbi:10090">mouse</span>
###xml 588 592 <span type="species:ncbi:10090">Mice</span>
###xml 707 711 <span type="species:ncbi:10090">mice</span>
###xml 970 974 <span type="species:ncbi:10090">mice</span>
###xml 1519 1523 <span type="species:ncbi:10090">mice</span>
###xml 1659 1663 <span type="species:ncbi:10090">mice</span>
To investigate effects of overexpression of Ahi-1 on the ability of transduced cells to induce leukemias in vivo, we injected transduced cells into sublethally irradiated NOD/SCID-beta2 microglobulin (beta2m)-/- mice. Strikingly, mice injected intravenously with Ahi-1-transduced BaF3 cells had a lethal leukemia within 70 d (5 x 106 cells/per mouse; Fig. 1 A). Disease latency was shortened to 40 d with BCR-ABL-transduced cells alone. Leukemogenic activity was further increased by introduction of cotransduced Ahi-1 and BCR-ABL cells, producing a latency of 26 d (P < 0.05; Fig. 1 A). Mice injected with either parental BaF3 cells or vector control cells had no evidence of disease after 120 d. Leukemic mice injected with either Ahi-1 or BCR-ABL-transduced cells developed splenomegaly and hepatomegaly, with 50-90% of YFP+/Ahi-1+, GFP+/BCR-ABL+, or both YFP+GFP+ cells detectable in these tissues (Fig. 1 B). As expected, larger spleens and livers were observed in mice injected with both Ahi-1 and BCR-ABL-transduced cells (Fig. 1 B and Table I). Interestingly, despite the apparently homogeneous pro-B cell phenotype of BaF3 cells transplanted, the leukemias generated from Ahi-1-transduced cells revealed multilineage features that included the production of Gr-1+Mac-1+ (myeloid), Ter119+ (erythroid), B220+ (B-lineage), and CD4+CD8+ (T-lineage; Fig. 1 C), suggesting that overexpression of Ahi-1 induces abnormal differentiation (including lineage switching) in hematopoietic cells. This was also observed in mice injected with Ahi-1 and BCR-ABL cotransduced cells. In addition, YFP+/Ahi-1+ or GFP+/BCR-ABL+ cells purified from BM cells of diseased mice showed increased proliferation and reduced apoptosis compared with control BaF3 cells; these effects were enhanced in Ahi-1- and BCR-ABL-cotransduced cells (Fig. S2 available at ). Thus, overexpression of Ahi-1 alone in IL-3-dependent hematopoietic cells has strong transforming activity in vitro and in vivo, and this is additive with the effects of BCR-ABL.
###end p 11
###begin p 12
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 0 121 0 121 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Overexpression of <italic>Ahi-1</italic> induces a lethal leukemia in vivo and these effects can be enhanced by cotransduction of BCR-ABL.</bold>
###xml 160 163 157 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 189 190 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 223 228 220 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 230 237 227 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 243 261 240 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1 plus BCR-ABL</italic>
###xml 383 388 380 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 407 414 404 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 461 466 458 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 471 474 468 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR</italic>
###xml 475 479 472 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABL.</italic>
###xml 504 505 501 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 595 600 592 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 651 652 648 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 164 168 <span type="species:ncbi:10090">mice</span>
###xml 268 272 <span type="species:ncbi:10090">mice</span>
###xml 345 349 <span type="species:ncbi:10090">mice</span>
###xml 555 560 <span type="species:ncbi:10090">mouse</span>
Overexpression of Ahi-1 induces a lethal leukemia in vivo and these effects can be enhanced by cotransduction of BCR-ABL. (A) Survival curves of NOD/SCID-beta2M-/- mice injected with 5 x 106 BaF3 cells transduced with MIY, Ahi-1, BCR-ABL, and Ahi-1 plus BCR-ABL. 8-10 mice were used per each group. (B) Spleen (top) and liver (bottom) weight of mice injected with MIY control cells, Ahi-1-transduced cells, BCR-ABL-transduced cells, and cells cotransduced with Ahi-1 and BCR-ABL. (C) FACS profiles of YFP+ BM cells isolated from a representative moribund mouse with leukemia, after injection of Ahi-1-transduced cells and showing expression by the YFP+ cells of Gr-1/Mac-1, B220, CD4/CD8, Ter119, Sac-1, and c-kit.
###end p 12
###begin p 13
###xml 36 40 <span type="species:ncbi:10090">mice</span>
Pathological parameters of leukemic mice injected with transduced cells in vivo
###end p 13
###begin p 14
Time (in days) to death caused by leukemia.
###end p 14
###begin title 15
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 130 137 130 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 60 65 <span type="species:ncbi:10090">mouse</span>
Overexpression of Ahi-1 alone confers a growth advantage on mouse hematopoietic stem/progenitor cells and enhances the effects of BCR-ABL
###end title 15
###begin p 16
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 89 96 89 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 453 454 453 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 457 458 457 458 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 461 462 461 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 469 470 469 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 478 479 478 479 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 482 483 482 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 486 487 486 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 496 497 496 497 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 509 510 509 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 513 514 513 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 517 518 517 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 521 522 521 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 529 530 529 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 537 538 537 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 572 577 572 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 613 618 613 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 714 719 714 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 774 781 774 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 838 846 838 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 907 908 907 908 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 911 912 911 912 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 915 916 915 916 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 923 924 923 924 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1031 1039 1031 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 1039 1047 1039 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">). Ahi-1</italic>
###xml 1064 1065 1064 1065 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1068 1069 1068 1069 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1260 1261 1260 1261 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1315 1330 1303 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, C and D</xref>
###xml 1464 1465 1452 1453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1468 1469 1456 1457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1474 1475 1462 1463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1538 1546 1526 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 E</xref>
###xml 1667 1674 1655 1662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1716 1721 1704 1709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 1726 1733 1714 1721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1821 1828 1809 1816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1849 1854 1837 1842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 1882 1888 1870 1876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 1915 1920 1903 1908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 2038 2045 2026 2033 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 212 217 <span type="species:ncbi:10090">mouse</span>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
###xml 1974 1979 <span type="species:ncbi:10090">mouse</span>
To further investigate the role of Ahi-1 as a potential cooperating oncogene relevant to BCR-ABL-mediated transformation in primitive primary hematopoietic cells, we compared the biological behavior of primitive mouse hematopoietic cells from the BM of 5-FU-treated adult C57BL/6 mice after transduction with MSCV-Ahi-1-IRES-YFP and MSCV-BCR-ABL-IRES-GFP retroviruses, alone or in combination. Q-RT-PCR analysis of RNA from FACS-purified primitive Sca-1+lin-YFP+ (Ahi-1+), Sca-1+lin-GFP+ (BCR-ABL+), and Sca-1+lin-YFP+GFP+ (Ahi-1+BCR-ABL+)-transduced BM cells showed that Ahi-1 transcripts were 40-fold higher in Ahi-1-transduced cells compared with cells transduced with control vector (MIY). Elevated endogenous Ahi-1 expression was also observed in cells transduced with BCR-ABL alone as compared with control cells (8-fold; P < 0.01; Fig. 2 A). 5 d after transduction, the rate of expansion of the Sca-1+lin-YFP+ (Ahi-1+) cells in liquid cultures was approximately twofold higher than in cultures initiated with control cells (Fig. 2 B). Ahi-1-transduced Sca-1+lin- cells produced a slightly greater number of colony-forming cells (CFCs) than MIY-transduced control cells in semisolid cultures in the presence of growth factors (GFs), and some of the Ahi-1+ CFCs (approximately15%) were already GF independent (Fig. 2, C and D). After 4 wk in long-term culture-initiating cell (LTC-IC) assays, which are used to measure stem cell activities in vitro, the Sca-1+lin-Ahi-1+ cells produced 3-fold more CFCs than control cells (P < 0.01; Fig. 2 E). All of these endpoints (proliferative activity, GF dependence, and CFC output in LTC-IC assays) are also perturbed by BCR-ABL transduction. In cells cotransduced with Ahi-1 and BCR-ABL, all of these effects were further enhanced compared with cells transduced with either BCR-ABL alone (2-4-fold) or Ahi-1 alone (3-6-fold; P < 0.01; Fig. 2). Thus, overexpression of Ahi-1 alone deregulates proliferative control of primitive mouse hematopoietic cells, and these effects can be enhanced by BCR-ABL.
###end p 16
###begin p 17
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 36 37 36 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 144 151 144 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 0 152 0 152 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Overexpression of <italic>Ahi-1</italic> in Sca-1<sup>+</sup>lin<sup>&#8722;</sup> mouse stem/progenitor BM cells perturbs their in vitro proliferative activity and enhances the effects of <italic>BCR-ABL</italic>.</bold>
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 201 206 201 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 236 237 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 240 241 240 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 244 245 244 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 248 253 248 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 260 261 260 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 264 265 264 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 268 269 268 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 272 279 272 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 286 287 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 290 291 290 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 294 295 294 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 302 307 302 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 313 320 313 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 327 328 327 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 331 332 331 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 335 336 335 336 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 339 340 339 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 38 43 <span type="species:ncbi:10090">mouse</span>
###xml 361 366 <span type="species:ncbi:10090">mouse</span>
###xml 618 623 <span type="species:ncbi:10090">mouse</span>
Overexpression of Ahi-1 in Sca-1+lin- mouse stem/progenitor BM cells perturbs their in vitro proliferative activity and enhances the effects of BCR-ABL. (A) The levels of Ahi-1 transcripts relative to GAPDH from FACS-purified MIY (Sca-1+lin-YFP+), Ahi-1 (Sca-1+lin-YFP+), BCR-ABL (Sca-1+lin-GFP+), and Ahi-1 plus BCR-ABL (Sca-1+lin-YFP+GFP+) transduced primary mouse BM cells. (B) Growth of each FACS-purified population with GFs. Viable cell numbers were determined by hematocytometer counts of trypan blue-excluding cells. (C) Number of CFC colonies produced in semisolid cultures +/- GF from the same FACS-purified mouse BM cells. (D) The appearance of GF-independent CFC colonies is shown. Bar, 250 mum. (E) The numbers of LTC-IC-derived CFCs produced from the same cells +/- GF. Values shown are the mean +/- SEM of triplicate measurements. * indicates significantly different from MIY control cells.
###end p 17
###begin title 18
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
Suppression or overexpression of AHI-1 mediates transforming activity of K562 CML cells in vitro and in vivo
###end title 18
###begin p 19
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 156 161 156 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 273 278 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 432 440 432 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 473 478 473 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 561 569 561 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 648 653 648 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 718 726 718 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 C</xref>
###xml 877 885 877 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 D</xref>
###xml 925 930 925 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1103 1118 1099 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, B and C</xref>
###xml 1268 1273 1264 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1275 1286 1271 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, A&#8211;C</xref>
###xml 114 119 <span type="species:ncbi:9606">human</span>
###xml 204 211 <span type="species:ncbi:9606">patient</span>
###xml 919 924 <span type="species:ncbi:9606">human</span>
To investigate directly whether deregulated expression of AHI-1 contributes to BCR-ABL-mediated transformation of human CML, knockdown or overexpression of AHI-1 in K562 cells, a cell line derived from a patient with CML and characterized by highly increased expression of AHI-1 (22), was performed, with confirmed down-regulation of AHI-1 in suppressed cells (AHI/sh4) and overexpression of AHI-1 in overexpressed cells (P < 0.01; Fig. 3 A). Interestingly, suppression of AHI-1 expression reduced GF independence in semisolid cultures (up to 5-fold; P < 0.01; Fig. 3 B) compared with cells transduced with control vector (RPG). Colonies formed by AHI-1-suppressed cells were much smaller than those of control cells (Fig. 3 C). Also, the ability to form a clone from a single cell was 2-fold less than that of the controls without GFs in liquid suspension cultures (P < 0.05; Fig. 3 D). In contrast, overexpression of human AHI-1 by transduction of EF1alpha-AHI-1-IRES-YFP lentivirus in K562 cells resulted in sharply increased colony-forming ability compared with control cells (1.5-2-fold; P < 0.05; Fig. 3, B and C). Importantly, restored expression of AHI-1 both at RNA and protein levels in AHI/sh4 cells reversed growth deficiencies exhibited by suppression of AHI-1 (Fig. 3, A-C).
###end p 19
###begin p 20
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 0 115 0 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Knockdown or overexpression of <italic>AHI-1</italic> in human K562 cells mediates their transforming activity in vitro and in vivo.</bold>
###xml 155 160 155 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 185 190 185 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 279 284 279 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 326 331 326 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 370 375 370 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 926 929 918 921 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 971 972 963 964 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 1071 1072 1061 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 40 45 <span type="species:ncbi:9606">human</span>
###xml 930 934 <span type="species:ncbi:10090">mice</span>
Knockdown or overexpression of AHI-1 in human K562 cells mediates their transforming activity in vitro and in vivo. (A) Q-RT-PCR analysis of the levels of AHI-1 transcripts relative to GAPDH in FACS-purified RPG vector-transduced K562 cells, AHI-1/sh4 cells (with suppression of AHI-1), AHI/sh4 + AHI-1 cells (coexpression of AHI-1 in AHI-1/sh4 cells), and AHI-1 cells (AHI-1 overexpressed cells, top). Western analysis (bottom) of AHI-1 expression in the same transduced cells with an anti-AHI-1 antibody. (B) The numbers of CFC colonies produced in semisolid cultures +/- GF (IL-3, GM-CSF, SF) in the same transduced cells. (C) The appearance of CFC colonies produced in semisolid cultures +/- GF as shown in B. Bar, 250 mum. (D) Percentage of single control K562 cells or AHI/sh4 cells generating clones (top) and clone size distributions obtained from these cells after being cultured for 7 d (bottom). (E) NOD/SCID-beta2M-/- mice were injected subcutaneously with 107 control K562 and transduced cells. Tumor volume is expressed as mean +/- SEM areas of each group (n = 4). (F) The appearance of tumors generated by the same cells as shown in E. Values shown are the mean +/- SEM of triplicate measurements. * indicates significantly different from K562 or RPG control cells.
###end p 20
###begin p 21
###xml 77 80 74 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 214 219 211 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 313 328 310 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, E and F</xref>
###xml 344 349 341 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 591 596 588 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 664 669 661 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
###xml 673 678 <span type="species:ncbi:9606">human</span>
To determine if in vitro effects could be replicated in vivo, NOD/SCID-beta2m-/- mice were injected subcutaneously with transduced cells to determine their ability to form tumors in vivo. Cells with suppression of AHI-1 failed or had significantly reduced ability to form tumors compared with control K562 cells (Fig. 3, E and F). In contrast, AHI-1 overexpressed cells rapidly generated larger tumors than the control cells within 3 wk (3-fold; P < 0.01). Strikingly, AHI/sh4 cells cotransduced with the AHI-1 construct could reverse in vivo growth deficiencies resulting from knockdown of AHI-1. These results demonstrate that modulation of expression levels of AHI-1 in human CML cells regulates their transforming activity in vitro and in vivo.
###end p 21
###begin title 22
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 45 52 45 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 64 69 <span type="species:ncbi:9606">human</span>
Suppression of AHI-1 expression in primitive BCR-ABL-transduced human CB cells and primary CML stem/progenitor cells reduces their growth autonomy
###end title 22
###begin p 23
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 61 68 61 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 125 126 125 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 130 131 130 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 221 226 221 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 314 322 314 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 340 347 340 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 454 461 454 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 499 504 499 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 543 544 543 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 560 561 560 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 579 580 579 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 594 595 594 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 624 625 624 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 631 639 631 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 653 660 653 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 701 706 701 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 755 762 755 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 794 802 794 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 C</xref>
###xml 970 977 970 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1125 1133 1121 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 C</xref>
###xml 1136 1138 1132 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 1156 1161 1152 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1176 1183 1172 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 90 95 <span type="species:ncbi:9606">human</span>
We next evaluated the effects of down-regulation of AHI-1 in BCR-ABL-transduced primitive human CB stem/progenitor cells (Lin-CD34+) using lentiviral-mediated RNA interference. Q-RT-PCR analysis indicated that endogenous AHI-1 expression was suppressed by 40-50% when the shRNA construct (AHI/sh4) was introduced (Fig. 4 A). Interestingly, BCR-ABL-transduced CB cells expanded rapidly in the presence or absence of GFs as expected, but the growth of the BCR-ABL-transduced cells with suppression of AHI-1 was significantly suppressed (2.2 x 106 versus 4.8 x 105 cells with GF; 106 versus 5 x 103 cells without GF; P < 0.01; n = 3; Fig. 4 B). Similarly, BCR-ABL-transduced CB cells with suppression of AHI-1 had up to 10-fold less CFC output compared with BCR-ABL-transduced CB cells (P < 0.01; Fig. 4 C). A similar reduction of CFC output was observed in the absence of GFs (data not shown). Notably, burst-forming-units-erythroids (BFU-Es) were especially increased in BCR-ABL-transduced CB cells compared with control cells, which remained predominantly myeloid as previously reported (110 +/- 8 versus 18 +/- 3; P < 0.01; Fig. 4 C) (25). Suppression of AHI-1 expression in BCR-ABL-transduced CB cells significantly reduced myeloid CFC (BFU-E and colony-forming units-granulocyte-macrophage [CFU-GM]) output, as well as primitive myeloid progenitors (colony-forming units-granulocyte-erythrocite-monocyte-megakaryocyte [CFU-GEMM]), suggesting that AHI-1 may play a role in regulation of overproduction of myeloid cells in CML.
###end p 23
###begin p 24
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 113 120 113 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 0 147 0 147 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Lentiviral-mediated suppression of <italic>AHI-1</italic> expression causes reduced proliferative activity and GF independence of <italic>BCR-ABL</italic>&#8211;transduced human CB cells.</bold>
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 223 228 223 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 246 247 246 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 251 252 251 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 355 360 355 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 363 370 363 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 823 830 819 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 882 889 878 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 132 137 <span type="species:ncbi:9606">human</span>
###xml 187 192 <span type="species:ncbi:9606">human</span>
Lentiviral-mediated suppression of AHI-1 expression causes reduced proliferative activity and GF independence of BCR-ABL-transduced human CB cells. (A) Q-RT-PCR analysis of the levels of human AHI-1 transcripts relative to GAPDH in transduced lin-CD34+ CB cells, including cells transduced with a control vector (Ctrl), AHI/sh4 cells (with suppression of AHI-1), BCR-ABL (B/A), and AHI/sh4 cotransduced cells (B/A + AHI/sh4). (B) Growth of each transduced population in suspension cultures +/- GF for 12 d. Viable cell numbers were determined by hematocytometer counts of trypan blue-excluding cells. (C) Number of BFU-E, CFU-GM, and CFU-GEMM colonies produced in semisolid cultures from the same cells as shown in B. Values shown are the mean +/- SEM of triplicate measurements. * indicates significant difference between BCR-ABL-transduced cells alone and cells cotransduced with BCR-ABL and AHI/sh4.
###end p 24
###begin p 25
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 135 136 135 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 140 141 140 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 321 326 321 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 358 359 358 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 363 364 363 364 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 448 456 448 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 476 477 476 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 481 482 481 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 518 519 518 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 523 524 523 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 580 585 580 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 666 674 666 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 680 681 680 681 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 685 686 685 686 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 763 768 763 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 844 849 844 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 898 899 898 899 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 903 904 903 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1054 1059 1054 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1138 1139 1126 1127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1143 1144 1131 1132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1194 1199 1182 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1254 1269 1230 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, B and C</xref>
###xml 1325 1330 1301 1306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1422 1430 1398 1406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 D</xref>
###xml 1612 1620 1588 1596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 170 178 <span type="species:ncbi:9606">patients</span>
###xml 275 283 <span type="species:ncbi:9606">patients</span>
###xml 400 407 <span type="species:ncbi:9606">patient</span>
###xml 711 719 <span type="species:ncbi:9606">patients</span>
###xml 1009 1017 <span type="species:ncbi:9606">patients</span>
###xml 1164 1171 <span type="species:ncbi:9606">patient</span>
To further elucidate the role of AHI-1 in primary CML stem/progenitor cells, AHI-1 transcript levels were evaluated in pretreatment lin-CD34+ cells from 16 chronic phase patients with subsequent clinical responses to IM therapy (6 responders and 10 nonresponders) and from 7 patients in blast crisis. Increased levels of AHI-1 expression were observed in lin-CD34+ CML stem/progenitor cells from all patient samples studies (2.5-18-fold; P < 0.04; Fig. 5 A), compared with lin-CD34+ normal BM cells. Interestingly, lin-CD34+ cells from IM nonresponders expressed higher levels of AHI-1 transcripts compared with the same cells isolated from IM responders (P = 0.03; Fig. 5 A). Lin-CD34+ cells from blast crisis patients also expressed relatively higher levels of AHI-1 transcripts (P < 0.03, compared with IM responders). A lentiviral-mediated AHI-1 shRNA construct was directly transduced into lin-CD34+ stem/progenitor cells isolated from three IM responders, three IM nonresponders, and three blast crisis patients. Lentiviral-mediated suppression of AHI-1 expression resulted in a reduction in CFC output by approximately28-60% in lin-CD34+ CML cells from all patient samples studied (with AHI-1 expression partially suppressed (approximately40-55%; Fig. 5, B and C). CFC colonies formed by CML cells with suppression of AHI-1 were found to be smaller than those resulting from cells transduced with a control vector (Fig. 5 D). It was interesting that more significant reduction in CFC numbers was observed in transduced primary CML cells from IM nonresponders and blast crisis compared with IM responders (Fig. 5 C).
###end p 25
###begin p 26
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 0 143 0 143 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Elevated <italic>AHI-1</italic> transcript levels in CML stem/progenitor cells and reduced CFC production in the same cells when <italic>AHI-1</italic> expression is suppressed.</bold>
###xml 189 194 189 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 231 232 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 236 237 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 270 271 270 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 275 276 275 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 394 399 394 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 424 429 424 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 447 448 447 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 452 453 452 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 573 578 571 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 739 740 737 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 743 744 741 742 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 183 188 <span type="species:ncbi:9606">human</span>
###xml 339 347 <span type="species:ncbi:9606">patients</span>
###xml 388 393 <span type="species:ncbi:9606">human</span>
###xml 544 552 <span type="species:ncbi:9606">patients</span>
###xml 939 946 <span type="species:ncbi:9606">patient</span>
Elevated AHI-1 transcript levels in CML stem/progenitor cells and reduced CFC production in the same cells when AHI-1 expression is suppressed. (A) Q-RT-PCR analysis of the levels of human AHI-1 transcripts relative to GAPDH in lin-CD34+ normal bone marrow (NBM) and lin-CD34+ CML cells from IM responders, nonresponders, and blast crisis patients. (B) Q-RT-PCR analysis of the levels of human AHI-1 transcripts relative to GAPDH in transduced lin-CD34+ normal BM and CML cells (three IM responders, three nonresponders, and three blast crisis patients) +/- suppression of AHI-1 expression, including cells transduced with a control vector (Ctrl) or a AHI/sh4 vector. (C) The yield of BFU-E, CFU-GM, and CFU-GEMM colonies from primary CD34+lin- CML cells transduced with a control vector or AHI/sh4 vector. (D) The appearance of CFC colonies produced in semisolid cultures from control and AHI/sh4-transduced cells from an IM nonresponder patient. Bar, 100 mum. Values shown are the mean +/- SEM of triplicate measurements. * indicates significant difference between transduced control cells and cells transduced with AHI/sh4 vector.
###end p 26
###begin title 27
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 86 93 86 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 93 94 93 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Coexpression of Ahi-1 in BCR-ABL-inducible cells regulates transforming activities of BCR-ABL+ cells
###end title 27
###begin p 28
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 72 79 72 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 141 146 141 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 152 159 152 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 226 233 226 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</sup>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 507 513 507 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 528 544 528 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 (A and B)</xref>
###xml 669 677 669 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 723 724 711 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 742 750 730 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 896 904 884 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 943 950 931 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1044 1059 1032 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6, C and D</xref>
###xml 1093 1098 1081 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 1125 1132 1113 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1263 1264 1251 1252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1353 1360 1341 1348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1387 1388 1363 1364 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 1398 1399 1374 1375 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1498 1504 1462 1468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 1618 1625 1582 1589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1773 1780 1737 1744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1849 1854 1813 1818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 1878 1886 1842 1850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 C</xref>
###xml 1944 1949 1908 1913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 2036 2043 2000 2007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 2108 2113 2072 2077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 2117 2124 2081 2088 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
To further investigate potential regulatory roles of Ahi-1 in mediating BCR-ABL-transforming activities, we evaluated cooperative effects of Ahi-1 in a BCR-ABL-transduced BaF3 cell line in which the level of expression of p210BCR-ABL can be variably down-regulated by exposure to doxycycline (Dox) (26). Reduction in BCR-ABL protein expression in the presence of Dox results in a corresponding decrease in GF independence of BaF3 cells both in liquid suspension cultures and in semisolid cultures in vitro (Fig. 6). As shown in Fig. 6 (A and B), cell growth and survival was dramatically reduced when Dox was added to culture at 48 h (>90% inhibition of proliferation, Fig. 6 A, right; approximately50% detectable Annexin V+ apoptotic cells, Fig. 6 B, top right), while the same cells showed a marked increase in cell expansion in the absence of both IL-3 and Dox (no down-regulation of BCR-ABL, Fig. 6 A, left). Similarly, down-regulation of BCR-ABL expression completely inhibited CFC generation in semisolid cultures in the absence of IL-3 (Fig. 6, C and D). Interestingly, introduction of Ahi-1 into cells with inhibited BCR-ABL expression under these stringent conditions enabled them to grow continuously in liquid suspension culture, to have less Annexin V+ apoptotic cells, and to produce more factor-independent CFCs than cells transduced with BCR-ABL alone (approximately4 x 105 versus 103 cells after 48 h in liquid culture and approximately100 CFCs versus 0 in the CFC assay; P < 0.01; Fig. 6). These results were consistently observed in two individual clonal cell lines. In the presence of IL-3 and Dox, BCR-ABL-transduced BaF3 cells showed a significant reduction in CFC production; addition of IL-3 cannot rescue inhibitory effects caused by suppression of BCR-ABL expression. This can be enhanced significantly by cotransduction of Ahi-1 (10-15-fold; P < 0.01; Fig. 6 C). Collectively, these results demonstrate the ability of Ahi-1 to immediately reverse in vitro growth deficiencies resulting from down-regulation of BCR-ABL in vitro, and provide direct evidence of the regulatory role of Ahi-1 in BCR-ABL-mediated transformation.
###end p 28
###begin p 29
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 80 87 80 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 0 131 0 131 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Overexpression of <italic>Ahi-1</italic> rescues growth suppression induced by the inhibition of <italic>BCR-ABL</italic> expression in BCR-ABL&#8211;inducible BaF3 cells.</bold>
###xml 160 167 160 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 211 218 211 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 286 293 284 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 436 443 434 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 464 469 462 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 481 488 479 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 597 598 593 594 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 770 775 764 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 780 787 774 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 948 955 937 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1016 1021 1005 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
Overexpression of Ahi-1 rescues growth suppression induced by the inhibition of BCR-ABL expression in BCR-ABL-inducible BaF3 cells. (A) Growth of control BaF3, BCR-ABL-inducible cells, and two Ahi-1-transduced, BCR-ABL-inducible clonal lines without IL-3 +/- Dox (+Dox = suppression of BCR-ABL expression). Viable cell numbers were determined by hematocytometer counts of trypan blue-excluding cells. (B) Annexin V-PE/7-AAD staining of BCR-ABL-inducible cells and Ahi-1-transduced BCR-ABL-inducible cells (Ahi-1 + B/A-2) after culture without IL-3 +/- Dox for 24 and 48 h. Percentages of Annexin V+ cells are indicated. (C) CFC colonies produced in semisolid media +/- IL-3 and Dox from the same cells as shown in A. (D) The appearance of GF-independent CFC colonies in Ahi-1 and BCR-ABL-cotransduced cells without IL-3 +/- Dox. Bar, 250 mum. Values shown are the mean +/- SEM of triplicate measurements. * indicates significant difference between BCR-ABL inducible cells alone and inducible cells cotransduced with Ahi-1.
###end p 29
###begin title 30
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
Coexpression of Ahi-1 in BCR-ABL-inducible cells sustains tyrosine phosphorylation of BCR-ABL and enhances activation of JAK2 and STAT5
###end title 30
###begin p 31
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 46 53 46 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 350 357 350 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 453 460 453 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 503 511 503 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
###xml 523 530 523 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 572 580 572 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL&#8211;</italic>
###xml 585 590 585 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 687 692 687 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 807 815 807 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
###xml 862 869 862 869 <sup xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</sup>
###xml 910 915 910 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 921 928 921 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 966 973 966 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1104 1119 1092 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, B and C</xref>
###xml 1447 1454 1435 1442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1565 1572 1553 1560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
To determine whether coexpression of Ahi-1 in BCR-ABL-inducible BaF3 cells influences protein expression and tyrosine kinase activity of BCR-ABL, and candidate downstream signaling that reflects enhanced transforming phenotypes observed, we performed Q-RT-PCR and Western blot analyses in these cells in the presence and absence of Dox. As expected, BCR-ABL transcripts were highly expressed without Dox and down-regulated in the presence of Dox in the BCR-ABL-inducible cells after 24-48 h in culture (Fig. 7 A). Elevated BCR-ABL transcript levels were again observed in BCR-ABL- and Ahi-1-cotransduced cells generated from two individual cells lines (3-6-fold; P < 0.01). As expected, Ahi-1 transcripts were highly elevated in cotransduced cells when compared with control BaF3 cells (>50-fold; P < 0.01; Fig. 7 A). Strikingly, tyrosine phosphorylation of p210BCR-ABL could not sufficiently be suppressed in Ahi-1- and BCR-ABL-cotransduced cells, as compared with BCR-ABL-transduced cells alone in the presence of the same amount of Dox (30-40% inhibition versus approximately80% inhibition; P < 0.01; Fig. 7, B and C). In all cases, BCR-ABL phosphorylation was not completely suppressed after 24 h in culture with addition of Dox. These results were consistently observed in two individual cotransduced cell lines. Similarly, BCR-ABL protein expression was also suppressed to a lesser degree in cotransduced cells than in cells transduced with BCR-ABL only, and Ahi-1 protein expression was found to be higher in cotransduced cells than in cells transduced with BCR-ABL only.
###end p 31
###begin p 32
###xml 65 72 65 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</sup>
###xml 76 83 76 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 0 129 0 129 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Sustained tyrosine phosphorylation and protein expression of P210<sup>BCR-ABL</sup> in <italic>BCR-ABL</italic>&#8211;inducible BaF3 cells cotransduced with <italic>Ahi-1</italic>.</bold>
###xml 169 176 169 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 188 193 188 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 226 231 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 249 256 249 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 281 287 281 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1-</italic>
###xml 298 305 298 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 526 533 524 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</sup>
###xml 580 587 578 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 717 724 713 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 789 794 785 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
Sustained tyrosine phosphorylation and protein expression of P210BCR-ABL in BCR-ABL-inducible BaF3 cells cotransduced with Ahi-1. (A) Q-RT-PCR analysis of the levels of BCR-ABL (left) and Ahi-1 (right) transcripts relative to GAPDH in control BaF3, BCR-ABL inducible cells and two Ahi-1-transduced BCR-ABL inducible clonal lines cultured without IL-3 +/- Dox for 24 h. (B) Western analyses of cell lysates from the same cells for 24 h. Antibodies used are indicated. (C) Tyrosine phosphorylation and protein expression of p210BCR-ABL and Ahi-1 relative to actin, as compared with BCR-ABL-transduced cells alone. Values shown are the mean +/- SEM of triplicate measurements. * indicates significant difference between BCR-ABL-inducible cells alone and the inducible cells cotransduced with Ahi-1.
###end p 32
###begin p 33
###xml 291 298 287 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 319 324 315 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 338 345 334 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 396 411 392 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8, A and B</xref>
###xml 667 675 663 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 A</xref>
We next evaluated the effect of increased BCR-ABL expression and tyrosine phosphorylation of cotransduced cells on the activity of candidate signaling mechanisms. We observed increased levels of phosphorylation of JAK2, STAT5, NF-kappaB p65 (at Ser 563 and Ser 468), and Src (at Tyr 416) in BCR-ABL-inducible cells and Ahi-1-cotransduced BCR-ABL-inducible cells compared with control BaF3 cells (Fig. 8, A and B). Interestingly, phosphorylation of most downstream proteins was down-regulated when BCR-ABL expression was inhibited by Dox, but sustained phosphorylation of JAK2 and STAT5 was consistently observed in cotransduced cells in the presence of IL-3 and Dox (Fig. 8 A, lanes 6 and 8 compared with lane 4). In the absence of IL-3, phosphorylation of JAK2 and STAT5 was reduced in cotransduced cells when BCR-ABL expression was suppressed. A similar, albeit less pronounced, finding of sustained phosphorylation of Src was also observed, particularly in Ahi-1 + BCR-ABL-1 cells in the presence of IL-3. These results suggest that Ahi-1 may play a regulatory role in mediation of BCR-ABL activity associated with enhanced activation of JAK2 and STAT5 through the IL-3 signaling pathway.
###end p 33
###begin p 34
###xml 41 48 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 0 172 0 172 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Enhanced activation of JAK2 and STAT5 in <italic>BCR-ABL</italic> inducible BaF3 cells cotransduced with <italic>Ahi-1</italic> and detection of a AHI-1&#8211;BCR-ABL&#8211;JAK2 interaction complex in human K562 cells.</bold>
###xml 273 278 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 290 297 290 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 467 468 465 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 495 496 493 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 155 160 <span type="species:ncbi:9606">human</span>
Enhanced activation of JAK2 and STAT5 in BCR-ABL inducible BaF3 cells cotransduced with Ahi-1 and detection of a AHI-1-BCR-ABL-JAK2 interaction complex in human K562 cells. (A and B) Western blot analyses of cell lysates from control BaF3, BCR-ABL-inducible cells, and two Ahi-1-transduced BCR-ABL-inducible clonal lines cultured in the presence (A) and absence (B) of IL-3 +/- Dox for 24 h. Antibodies used are indicated. (C-H) Protein lysates of K562 cells (BCR-ABL+) and Hut 78 cells (BCR-ABL-) were used to immunoprecipitate AHI-1 (C, E-F, and H), ABL (D), and JAK2 (G), and proteins were detected by Western blotting with antibodies to ABL (C), AHI-1 (D, F, and G), JAK-2 (G), and phosphotyrosine (E and H) as indicated. In H, before immunoprecipitation, lysates were incubated for 1 h with the indicated AHI-1 peptide; unrelated peptide (unr.), no peptide (-), and antigenic peptide (+) or cells were incubated +/- IM (5 muM) for 6 h before preparation of protein lysates.
###end p 34
###begin title 35
AHI-1 physically interacts with BCR-ABL
###end title 35
###begin p 36
###xml 303 311 303 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 C</xref>
###xml 357 358 357 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 380 388 380 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 C</xref>
###xml 576 584 576 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 D</xref>
###xml 628 635 628 635 <sup xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</sup>
###xml 747 755 747 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 E</xref>
###xml 872 880 872 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 E</xref>
###xml 1149 1157 1149 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 F</xref>
###xml 1487 1495 1487 1495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 G</xref>
###xml 1865 1873 1865 1873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 H</xref>
###xml 2115 2123 2114 2122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 H</xref>
###xml 242 247 <span type="species:ncbi:9606">human</span>
###xml 281 286 <span type="species:ncbi:9606">human</span>
To detect a physical interaction between AHI-1 and BCR-ABL in CML cells, coimmunoprecipitation (co-IP) experiments were performed. We demonstrated a direct interaction between AHI-1 and BCR-ABL at endogenous levels by detection of BCR-ABL in human CML cells (K562) after IP with a human AHI-1 antibody (Fig. 8 C). This interaction was not found in a BCR-ABL- T cell line (Hut 78; Fig. 8 C, lane 2) or in control antibody coimmunoprecipitated K562 cells (not depicted). The result was confirmed by detection of AHI-1 in the same cells after IP with a specific antibody to ABL (Fig. 8 D). Importantly, tyrosine phosphorylated p210BCR-ABL could be detected in K562 cells using an antiphosphotyrosine antibody (4G10) after IP with the AHI-1 antibody (Fig. 8 E). Interestingly, this protein interaction complex is also associated with a 120-kD tyrosine-phosphorylated protein (Fig. 8 E). To determine whether this 120-kD protein could be an AHI-1 isoform, the same membrane was washed and reprobed with an AHI-1 antibody. The full-length (150 kD) and a 100-kD isoform of AHI-1 protein (but not a 120-kD protein) were identified by Western blot analyses (Fig. 8 F). Using co-IP, we examined several candidate 120-kD tyrosine-phosphorylated proteins known to interact with BCR-ABL, including CBL and JAK2. We determined that JAK2 was associated with this protein interaction complex, as AHI-1 could be detected by an anti-AHI-1 antibody in K562 cells after IP with a specific antibody to JAK2 (Fig. 8 G); this interaction was further confirmed by reverse detection of JAK2 after IP with the anti-AHI-1 antibody (not depicted). In addition, the antigenic peptide derived from the sequence of AHI-1 specifically blocked the ability of the AHI-1 antibody to precipitate both tyrosine-phosphorylated BCR-ABL and the 120-kD protein, whereas an unrelated peptide had no effect (Fig. 8 H, lane 3). Interestingly, this interaction complex was found to be modulated by tyrosine kinase activity of BCR-ABL, as IM treatment (5 muM) of K562 cells for 6 h resulted in inability to detect both tyrosine-phosphorylated BCR-ABL and JAK2 (Fig. 8 H, lane 4). These results indicate that AHI-1 and BCR-ABL can interact and form a complex involving tyrosine-phosphorylated JAK2.
###end p 36
###begin title 37
###xml 35 36 35 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
AHI-1 regulates response of BCR-ABL+ primitive CML cells to TKIs
###end title 37
###begin p 38
###xml 108 109 108 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 117 124 117 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 185 190 185 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 254 261 253 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 459 467 444 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 A</xref>
###xml 511 516 496 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 521 528 506 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 661 669 646 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 A</xref>
###xml 878 886 863 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 A</xref>
###xml 924 929 909 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 995 996 980 981 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
To determine whether AHI-1-BCR-ABL-JAK2 interaction complex may mediate IM sensitivity/resistance of BCR-ABL+ cells, BCR-ABL-transduced inducible BaF3 cells and cells cotransduced with Ahi-1 were treated with various doses of IM (0-10 mum). As expected, BCR-ABL-transduced cells showed a significant reduction in CFC output in response to IM treatment in the presence and absence of IL-3 (approximately90% inhibition with 5 muM IM + IL-3 and 1 muM IM - IL-3; Fig. 9 A). Strikingly, BaF3 cells cotransduced with Ahi-1 and BCR-ABL showed no response to IM and produced as many CFCs in the presence of IL-3 as were produced by the same cells without IM treatment (Fig. 9 A, left). Moreover, cotransduced cells also displayed greater resistance to IM in CFC output in the absence of IL-3, although these cells were more sensitive to IM treatment than those in the presence of IL-3 (Fig. 9 A, right). These results indicate that Ahi-1 is capable of overcoming IM-induced growth suppression in BCR-ABL+ cells when IL-3 signaling is activated in these cells.
###end p 38
###begin p 39
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 107 108 107 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 100 108 100 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL<sup>+</sup></italic>
###xml 0 129 0 129 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>AHI-1</italic> mediates response/resistance of TKIs as assessed by overexpression or suppression of <italic>AHI-1</italic> in <italic>BCR-ABL<sup>+</sup></italic> primitive CML cells.</bold>
###xml 249 256 246 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 282 288 279 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1&#8211;</italic>
###xml 299 306 296 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 693 698 689 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 719 724 715 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 747 752 743 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1042 1043 1033 1034 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1047 1048 1038 1039 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1079 1080 1070 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1102 1103 1093 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1128 1129 1119 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1318 1325 1307 1314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1380 1385 1369 1374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 1402 1403 1391 1392 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1407 1408 1396 1397 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1135 1142 <span type="species:ncbi:9606">patient</span>
AHI-1 mediates response/resistance of TKIs as assessed by overexpression or suppression of AHI-1 in BCR-ABL+ primitive CML cells. (A) Percentage of inhibition of CFC colonies generated in semisolid media +/- IL-3 and IM (0-5 muM) from control BaF3, BCR-ABL-inducible cells, and two Ahi-1-transduced BCR-ABL-inducible clonal cell lines. (B) Model of AHI-1-BCR-ABL-JAK2 complex regulation of constitutive activation of BCR-ABL and JAK2-STAT5 pathway, resulting in increased proliferation and reduced TKI response of CML stem/progenitor cells. (C) Percentage of inhibition of CFC generation in semisolid media with GF and IM (0-10 muM) from control K562, AHI/sh4-transduced cells (suppression of AHI-1), overexpression of AHI-1 in AHI/sh4 cells, and AHI-1-transduced K562 cells. * indicates significantly different from K562 control cells. (D) Western analyses of cell lysates from the same cells +/- IM (5 muM) for 6 h. Antibodies used are indicated. (E) Inhibition of CFCs in semisolid media with IM (5 muM), DS (100 nM), and NL (5 muM) in lin-CD34+ CML cells from IM responders (n = 3), nonresponders (n = 3), and blast crisis (n = 3) patient samples transduced with either a control vector or AHI-1/sh4 vector. Values shown are the mean +/- SEM of triplicate measurements. * indicates significantly different between BCR-ABL-inducible cells and inducible cells cotransduced with Ahi-1, and between lin-CD34+ cells transduced with a control vector or transduced with the AHI-1/sh4 vector.
###end p 39
###begin p 40
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 202 210 190 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 C</xref>
###xml 240 245 228 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 399 404 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 478 483 465 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 526 534 513 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 C</xref>
###xml 641 646 628 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 719 724 706 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 751 759 738 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 D</xref>
###xml 1030 1031 1017 1018 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1174 1179 1161 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1222 1227 1209 1214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1299 1304 1286 1291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1372 1380 1359 1367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 D</xref>
###xml 29 34 <span type="species:ncbi:9606">human</span>
Similarly, overexpression of human AHI-1 in K562 cells resulted in greater resistance to IM treatment, as assessed by the CFC assay, (approximately2-fold; P < 0.01) in comparison to K562 control cells (Fig. 9 C). Conversely, suppression of AHI-1 (AHI/sh4) resulted in increased sensitivity to IM, particularly in the presence of a low concentration of IM (1 muM). Strikingly, restored expression of AHI-1 by overexpression of an AHI-1 construct in AHI/sh4 cells (suppression of AHI-1) restored IM resistance to AHI/sh4 cells (Fig. 9 C). Western analysis revealed increased tyrosine-phosphorylated BCR-ABL, JAK2, and STAT5 in K562 cells with AHI-1 overexpression and reduced levels of these phosphorylated proteins when AHI-1 expression is suppressed (Fig. 9 D). Interestingly, phosphorylated BCR-ABL, JAK2, and STAT5 levels could be restored in the AHI-1/sh4 cells when AHI-1 construct was reintroduced into the same cells. Importantly, expression of AHI-1 not only modulates phosphorylation of BCR-ABL, JAK2, and STAT5 in BCR-ABL+ K562 cells, but also regulates protein expression of these genes, as demonstrated by significantly enhanced expression of these proteins when AHI-1 is overexpressed, reduced expression when AHI-1 is suppressed, and restored expression in AHI-1-suppressed cells where AHI-1 expression has been rescued by introduction of an AHI-1 construct (Fig. 9 D). These results further support our findings in the BCR-ABL-inducible system that AHI-1 plays a critical role in mediation of BCR-ABL and JAK2-STAT5 activities.
###end p 40
###begin p 41
###xml 35 36 35 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 277 282 277 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 352 360 340 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 394 395 382 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 399 400 387 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 537 545 523 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 E</xref>
###xml 559 560 545 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 564 565 550 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 592 597 578 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 804 809 778 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 909 910 883 884 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 902 910 876 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL<sup>+</sup></italic>
###xml 240 248 <span type="species:ncbi:9606">patients</span>
###xml 679 687 <span type="species:ncbi:9606">patients</span>
We next assessed sensitivity of lin-CD34+ CML stem/progenitor cells, with and without suppression of AHI-1 expression, to the TKIs IM, DS, and NL. Cells were obtained from three IM responders, three IM nonresponders, and three blast crisis patients with partial suppression of AHI-1 expression in transduced CML cells (approximately40-50%) as shown in Fig. 5 B. Interestingly, in all cases, lin-CD34+ CML cells were more sensitive to DS treatment (100 nM) than to IM (5 muM) or NL (5 muM), as assessed by their ability to generate CFCs (Fig. 9 E), whereas lin-CD34+ cells with suppression of AHI-1 expression, particularly cells from the clinically IM-resistant and blast crisis patients, were more sensitive to all three inhibitors (approximately2-fold; P < 0.05). Collectively, these data suggest that AHI-1 plays an important role in modulating sensitivity to IM and other selective BCR-ABL TKIs in BCR-ABL+ CML cells.
###end p 41
###begin title 42
DISCUSSION
###end title 42
###begin p 43
###xml 54 65 54 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1/AHI-1</italic>
###xml 132 139 132 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 255 260 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 363 364 363 364 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 367 368 367 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 569 576 569 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 633 638 633 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 643 650 643 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 730 735 730 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 794 801 794 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 848 849 848 849 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 853 854 853 854 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 935 940 935 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1162 1167 1162 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1327 1332 1327 1332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1334 1340 1334 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 1356 1361 1356 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1376 1383 1376 1383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1557 1565 1557 1565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 C</xref>
###xml 1610 1617 1610 1617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1633 1634 1633 1634 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1747 1754 1747 1754 <sup xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</sup>
###xml 1765 1767 1765 1767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 1825 1830 1825 1830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 1898 1906 1898 1906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 1939 1950 1939 1950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1/AHI-1</italic>
###xml 2087 2089 2087 2089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 2091 2093 2091 2093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 2094 2096 2094 2096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 2127 2132 2127 2132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 2136 2143 2136 2143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 2198 2203 2198 2203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 2207 2214 2207 2214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 2293 2300 2293 2300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 2661 2672 2661 2672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1/AHI-1</italic>
###xml 2694 2695 2694 2695 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2687 2695 2687 2695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL<sup>+</sup></italic>
###xml 2890 2901 2890 2901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1/AHI-1</italic>
###xml 3009 3016 3009 3016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 3139 3150 3139 3150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1/AHI-1</italic>
###xml 3175 3182 3175 3182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 217 222 <span type="species:ncbi:10090">mouse</span>
###xml 249 254 <span type="species:ncbi:10090">mouse</span>
###xml 398 403 <span type="species:ncbi:10090">mouse</span>
###xml 716 721 <span type="species:ncbi:9606">human</span>
###xml 813 818 <span type="species:ncbi:9606">human</span>
###xml 1020 1027 <span type="species:ncbi:9606">patient</span>
###xml 1120 1127 <span type="species:ncbi:9606">patient</span>
###xml 1250 1258 <span type="species:ncbi:9606">patients</span>
###xml 1276 1284 <span type="species:ncbi:9606">patients</span>
###xml 1395 1400 <span type="species:ncbi:9606">human</span>
###xml 2495 2500 <span type="species:ncbi:9606">human</span>
In this study, we demonstrate for the first time that Ahi-1/AHI-1 is a new oncogene that cooperates in transforming activities with BCR-ABL both in vitro and in vivo through a direct physical interaction. First, in a mouse system, overexpression of mouse Ahi-1 confers a proliferative advantage in vitro to IL-3-dependent BaF3 cells and a stem cell-enriched Sca-1+lin- population from 5-FU-treated mouse BM cells, and induces a lethal leukemia in vivo. This deregulated proliferative activity, GF independence, and leukemogenic potential is enhanced by introduction of BCR-ABL. Thus, there is a direct biological correlation between Ahi-1 and BCR-ABL in regulating transforming activity of these cells. Second, in a human system, AHI-1 expression appears to regulate transforming activities of BCR-ABL-transduced human CB stem/progenitor cells (lin-CD34+), as indicated by their significantly reduced autonomous growth when endogenous AHI-1 expression is stably inhibited. These effects were further demonstrated in CML patient samples; reduced autonomous growth was observed in primary CML stem/progenitor cells in all patient samples studied with knockdown of AHI-1. The effects were more significant in CML stem/progenitor cells from IM-resistant patients and blast crisis patients who expressed relatively higher levels of AHI-1 (Fig. 5). Knockdown of AHI-1 expression in BCR-ABL-transduced human CB cells not only inhibited all differentiated myeloid cells (CFU-GM and CFU-GEMM) but also significantly inhibited differentiating erythroid cells (BFU-E; Fig. 4 C) that are produced at a high frequency from BCR-ABL-transduced CD34+ stem/progenitor cells independent of their apparent prior lineage commitment status caused by modulation of P210BCR-ABL activity (25). Interestingly, we also observed that overexpression of Ahi-1 in pro-B BaF3 cells altered their differentiation pattern in vivo (Fig. 1 C), suggesting that modulation of Ahi-1/AHI-1 expression alters progenitor cell differentiation, including lineage switching, as previous reports have suggested for other oncogenes (25, 27-30). Third, a regulatory role of Ahi-1 in BCR-ABL-mediated transformation is evident as coexpression of Ahi-1 in BCR-ABL-inducible cells can reverse growth deficiencies induced by down-regulation of BCR-ABL. This biological effect is associated with sustained phosphorylation of BCR-ABL and enhanced activities of JAK2-STAT5. Finally, an AHI-1-BCR-ABL--JAK2 interaction complex has been identified in human CML cells. This complex mediates sensitivity/resistance of primitive CML stem/progenitor cells to TKIs, as demonstrated by either coexpression or inhibition of Ahi-1/AHI-1 expression in BCR-ABL+ CML cells with a resulting modulation of CML cell sensitivity to these inhibitors. Collectively, these findings provide strong evidence of the importance of persistent deregulated expression of Ahi-1/AHI-1 to the sustained in vitro and in vivo transforming activities associated with CML and in the modulation of BCR-ABL-mediated malignant transformation and response of CML stem/progenitor cells to TKIs. This research has further identified Ahi-1/AHI-1 as a novel modulator of BCR-ABL that is specifically involved in the JAK2-STAT5 pathway.
###end p 43
###begin p 44
###xml 349 354 349 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 358 365 358 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 460 467 460 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 534 539 534 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 702 709 702 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 756 764 756 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 B</xref>
###xml 1089 1097 1089 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 B</xref>
###xml 1271 1278 1271 1278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 1318 1323 1318 1323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 1369 1375 1369 1375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 1610 1618 1610 1618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 D</xref>
###xml 1909 1910 1909 1910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 1912 1913 1912 1913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 1915 1917 1915 1917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 1935 1942 1935 1942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 2021 2023 2021 2023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 2046 2050 2046 2050 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-3</italic>
###xml 2067 2069 2067 2069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 2071 2073 2071 2073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 2212 2214 2209 2211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 2391 2392 2388 2389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2531 2533 2528 2530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 2589 2595 2586 2592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT5A</italic>
###xml 2600 2606 2597 2603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT5B</italic>
###xml 2725 2727 2722 2724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 2846 2847 2843 2844 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2906 2908 2903 2905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 2929 2934 2926 2931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT5</italic>
###xml 3012 3013 3009 3010 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 3045 3047 3042 3044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 3226 3233 3223 3230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 3299 3301 3296 3298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 3302 3304 3299 3301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 1449 1454 <span type="species:ncbi:9606">human</span>
###xml 3165 3170 <span type="species:ncbi:10090">mouse</span>
Identification of an AHI-1-BCR-ABL-JAK2 interaction complex raises many interesting questions about the nature of the interaction, how it is regulated, and how it contributes to malignant transformation, altered BCR-ABL signaling, and IM response/resistance of CML stem/progenitor cells. Particularly notable is the observation that coexpression of Ahi-1 in BCR-ABL-inducible cells can rescue GF-independent cell growth that is inhibited by down-regulation of BCR-ABL. Interestingly, this renewed GF independence with introduction of Ahi-1 appears to be regulated by sustained phosphorylation of BCR-ABL, rather than its continual expression, as these effects were observed in cotransduced cells where BCR-ABL expression was inducibly suppressed in vitro (Fig. 7 B). These results suggest that physical interaction between Ahi-1 and BCR-ABL may stabilize a protein-protein interaction complex that enables constitutively active BCR-ABL tyrosine kinase activity and further alters specific downstream BCR-ABL signaling pathways that deregulate cellular proliferation and apoptosis control (Fig. 9 B). This is further supported by identification of JAK2 as an associated protein in this interaction complex and observation of enhanced activity of the JAK2-STAT5 pathway in BCR-ABL-inducible cells with cotransduction of Ahi-1 in the presence of GF stimulation with IL-3 (Fig. 8). Interestingly, all these findings can be replicated significantly in a human CML cell line system in which changes in AHI-1 expression are found to modulate tyrosine phosphorylation and protein expression of BCR-ABL and JAK2-STAT5 (Fig. 9 D). It is known that BCR-ABL signaling closely mimics signaling pathways of cytokine receptors and that both IL-3/GM-CSF receptor activation and the BCR-ABL oncoprotein can induce a tyrosine phosphorylation cascade of which numerous proteins, including JAK2 and STAT5, are common substrates (5, 6, 31). Interestingly, BCR-ABL-expressing cells have many similarities to cells induced by IL-3 stimulation (32) or cells with forced IL-3 overexpression (33, 34). Early studies have shown that BCR-ABL can interact with the common beta chain of IL-3/GM-CSF receptor and constitutively activate JAK2 (35). In particular, increased phosphorylation of STAT5, which was previously thought to be an immediate function of the BCR-ABL oncoprotein, has now been shown in primary CML CD34+ progenitor cells to occur largely as a consequence of BCR-ABL-induced activation of IL-3 autostimulation, leading to activation of STAT5 (36). It has been reported that targeted disruption of the STAT5A and STAT5B genes reduces myeloid progenitor numbers, suggesting a nonredundant role for STAT5 in primitive normal hematopoiesis (37). Recent studies further suggest that autocrine production of GM-CSF may contribute to IM and NL-resistance in BCR-ABL+ progenitors through activation of JAK2 and STAT5 pathway (38), and inhibition of STAT5 expression by a shRNA approach significantly reduced colony formation of CD34+ CML progenitor cells in vitro (39). In addition, JAK2 is known to interact with the C-terminal region of BCR-ABL, and recent studies further show that mouse hematopoietic cells transformed by the T315I mutant of BCR-ABL can be induced to undergo apoptosis by a JAK2 inhibitor (AG490) (40-42). Collectively, these results indicate that activation of the JAK2-STAT5 pathway in CML stem/progenitors is likely to be an important mechanism contributing to responses to BCR-ABL-targeted therapies and identification of Ahi-1/AHI-1 as a novel mediator involved in this pathway suggests AHI-1 alone or in combination with JAK2 and STAT5, as potential additional therapeutic targets.
###end p 44
###begin p 45
###xml 75 82 75 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 147 158 147 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1/AHI-1</italic>
###xml 296 301 296 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 547 552 547 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 628 635 628 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 716 723 716 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 728 733 728 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 963 968 963 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1237 1239 1237 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 1241 1243 1241 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">43</xref>
###xml 1877 1879 1877 1879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 2000 2002 2000 2002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 2199 2204 2199 2204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 2208 2215 2208 2215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 2877 2882 2877 2882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 2895 2902 2895 2902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 2944 2950 2944 2950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 3156 3161 3156 3161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 3288 3290 3288 3290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 370 377 <span type="species:ncbi:9606">patient</span>
###xml 1037 1045 <span type="species:ncbi:9606">patients</span>
The most revealing result presented here is the finding that expression of BCR-ABL was consistently associated with an up-regulation of endogenous Ahi-1/AHI-1 transcripts and an increase in Ahi-1/AHI-1 protein expression in several overexpression and inducible experimental systems. Up-regulated AHI-1 expression has been noted in K562 cells, a cell line derived from a patient with CML in blast crisis (22). In particular, modulation of AHI-1 expression in K562 cells regulates BCR-ABL and JAK2-STAT5 activities, as described above. Importantly, AHI-1 is highly deregulated in primary CML stem/progenitor cells where levels of BCR-ABL transcripts are also highly elevated, suggesting that deregulated expression of BCR-ABL and AHI-1 may be clinically relevant to their cooperative activities that result in a permanently expanding clone of deregulated stem cells during leukemia development. Indeed, our study further demonstrates that highly elevated levels of AHI-1 in CML stem/progenitor cells from IM nonresponders and blast crisis patients correlate with their relative resistance to TKIs. Similarly, a potential mechanism for a physical interaction between Ahi-1/AHI-1 and BCR-ABL is revealed based on their molecular structures (20, 43), which are compatible with specific protein-protein interactions. Ahi-1 may interact with BCR-ABL through its SH3 domain or its SH3 binding sites (i.e., the SH3 domain of one protein interacting with the SH3 binding sites of the other) or through the SH2 domain of BCR-ABL if Ahi-1 is tyrosine phosphorylated (Ahi-1 contains two potential tyrosine phosphorylation sites). In addition, Ahi-1 may bind to a SH2-containing protein that is a substrate of BCR-ABL, thus forming a complex, as it is known that BCR-ABL is extensively tyrosine-phosphorylated, providing numerous, potential docking sites for SH2 domain-containing proteins (44). Moreover, Ahi-1 may interact with multiple domains of BCR-ABL, as demonstrated by other BCR-ABL-interacting proteins (45). Although more detailed structural mapping will be required to define specific protein-protein interactions between Ahi-1 and BCR-ABL, in association with JAK2, our findings that coexpression of Ahi-1 in BCR-ABL-transduced cells can completely rescue IM-induced suppression of cell growth in the presence of IL-3 suggests that Ahi-1 may not be a direct substrate of the BCR-ABL tyrosine kinase, but rather a modular protein that forms a stable protein interaction complex with other tyrosine phosphorylated proteins to mediate IL-3-dependent BCR-ABL and JAK2-STAT5 activities. In addition, this protein interaction complex seems to be disrupted by suppression of tyrosine phosphorylation of BCR-ABL by IM. Studies are underway to define how AHI-1 specifically interacts with BCR-ABL and JAK2. It was interesting to note that enhanced phosphorylation of Src was observed in Ahi-1 coexpressed BCR-ABL-inducible cells in the presence of IL-3 (Fig. 8), suggesting that other kinases are also activated with stimulation of IL-3 when BCR-ABL and AHI-1 are coexpressed. This finding also explains the observation that CML progenitor cells with suppression of AHI-1 experienced greater inhibition of CFC generation in response to dasatinib, a more potent TKI that also inhibits Src activity (14).
###end p 45
###begin p 46
In conclusion, our studies demonstrate that Ahi-1/AHI-1 is a novel BCR-ABL interacting protein that is also physically associated with JAK2. This AHI-1-BCR-ABL-AK2 complex seems to modulate BCR-ABL-transforming activity and TKI response/resistance of CML stem/progenitor cells through the IL-3-dependent BCR-ABL and JAK2-STAT5 pathway. These results suggest that a more promising potential therapeutic approach would be the combined suppression of BCR-ABL tyrosine kinase activity, Ahi-1/AHI-1 expression, and JAK2-STAT5 signaling.
###end p 46
###begin title 47
MATERIALS AND METHODS
###end title 47
###begin title 48
Retroviral and lentiviral vectors and virus production.
###end title 48
###begin p 49
###xml 110 115 110 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 193 200 193 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 323 330 323 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 604 609 604 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1022 1027 1014 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 1083 1085 1075 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 542 547 <span type="species:ncbi:9606">human</span>
###xml 1016 1021 <span type="species:ncbi:9606">human</span>
An MSCV-Ahi-1-IRES-YFP retroviral vector was constructed by ligating a 3.5-kb fragment containing full-length Ahi-1 cDNA (20) to the upstream IRES of the MIY vector. The MSCV-BCR-ABL-IRES-GFP (BCR-ABL) retroviral vector was constructed as previously described (46). To generate a BCR-ABL lentiviral vector, the full-length BCR-ABL cDNA (J. Griffin, Dana Farber Cancer Institute, Boston, MA) was cloned into the pMNDU3-pGK-eGFP lentiviral vector (D. Kohn, University of Southern California, Los Angeles, CA) through an EcoRI site. To generate human AHI-1 lentiviral vector, plasmid containing full-length AHI-1 cDNA (AL136797, obtained from Resource Center Primary Database, Berlin, Germany) was subcloned into the EF1alpha-IRES-YFP lentiviral vector (with substitution of eGFP with YFP from an EF1alpha-IRES-eGFP lentiviral vector; P. Leboulch, Massachusetts Institute of Technology, Boston, MA) between AscI and PacI sites. To generate the AHI sh4 lentiviral construct, the H1 promoter-driven small hairpin against human AHI-1 was released from a modified pSUPER AHI sh4 construct (23) and inserted into an EF1alpha-IRES-YFP lentiviral vector. A similar subcloning procedure was performed to insert only the H1 promoter into the BamHI site of the EF1alpha-IRES-YFP lentiviral vector as control. All constructs were verified by restriction enzyme digestion analysis and DNA sequencing.
###end p 49
###begin p 50
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">47</xref>
###xml 174 175 162 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 224 225 212 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 370 372 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">48</xref>
###xml 492 494 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 406 410 <span type="species:ncbi:9913">calf</span>
Lentiviral production was performed after a previously described procedure (47). The titers of these concentrated viruses were measured with HeLa cells as approximately1 x 108 infectious U/ml for the BCR-ABL virus and 2 x 108 infectious U/ml for control, AHI sh4, and AHI-1 viruses. Helper-free retrovirus was obtained by transfecting ecotropic Phoenix packaging cells (48) cultured in DMEM plus 10% fetal calf serum using the calcium-phosphate precipitation method, as previously described (46).
###end p 50
###begin title 51
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human primary cells and FACS sorting.
###end title 51
###begin p 52
###xml 101 102 101 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 126 127 126 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 42 50 <span type="species:ncbi:9606">patients</span>
###xml 323 330 <span type="species:ncbi:9606">infants</span>
Peripheral blood was obtained from 23 CML patients who had elevated white blood cell counts (105 x 109 cells/liter to 420 x 109 cells/liter) and had not been treated with any inhibitors, 10 of whom subsequently developed IM resistance. CB cells were obtained from mothers undergoing cesarean delivery of healthy, full-term infants. In all cases, informed consent was obtained, and the procedures used, including the Declaration of Helsinki protocol, were approved by the Research Ethics Board of the University of British Columbia (Vancouver).
###end p 52
###begin p 53
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 260 261 260 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 264 265 264 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 266 271 <span type="species:ncbi:10090">mouse</span>
Lin-CD34+ CB cells from six individuals were isolated using the EasySep cell separation kit (Stem Cell Technologies) according to the manufacturer's instruction. The purity of the enriched cells was measured by FACS as >95%. FACS isolation of BaF3 cells, Sca-1+lin- mouse BM cells, and K562 cells transduced with GFP, YFP, or GFP and YFP using a FACStar Plus or FACSVantage (BD Biosciences) was previously described (46).
###end p 53
###begin title 54
###xml 16 22 <span type="species:ncbi:10090">murine</span>
###xml 27 32 <span type="species:ncbi:9606">human</span>
Transduction of murine and human hematopoetic cells.
###end title 54
###begin p 55
###xml 481 482 481 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 835 837 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 34 38 <span type="species:ncbi:10090">mice</span>
###xml 240 245 <span type="species:ncbi:10090">mouse</span>
###xml 297 302 <span type="species:ncbi:10090">mouse</span>
###xml 346 351 <span type="species:ncbi:9606">human</span>
BM cells from 6-10-wk-old C57BL/6 mice were harvested 4 d after injection of 150 mg/kg 5-FU. Low-density cells were isolated and cultured for 48 h in serum-free medium (SFM) supplemented with BIT (StemCell Technologies), to which 100 ng/ml mouse Steel Factor (SF; STEMCELL Technologies), 10 ng/ml mouse IL-3 (StemCell Technologies), and 10 ng/ml human IL-6 (Cangene) were also added. The BM cells, as well as IL-3-dependent BaF3 cells, were then collected and resuspended at 5 x 105 cells/ml in VCS diluted 1:3 in DMEM containing 15% FCS, protamine sulfate (5 mug/ml), and SF, IL-3, and IL-6 at the same concentrations as described above. BaF3 cells were cultured with IL-3 only. The cells were then transferred to Petri dishes that had been precoated with fibronectin (Sigma-Aldrich) and preloaded with virus as previously described (46).
###end p 55
###begin p 56
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 119 126 119 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 163 164 163 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 206 207 206 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 214 215 214 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 374 375 374 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 378 379 378 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 394 395 394 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 404 405 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 451 452 451 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 456 457 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 620 621 620 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 625 626 625 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
CD34+ CB cells were prestimulated with a cocktail of cytokines and transduced with virus as previously described (25). BCR-ABL-transduced cells were sorted for GFP+ cells after 3 d of culture and sorted GFP+BCR-ABL+ cells were retransduced with either control or AHI/sh4 virus. Cells transduced with only control or AHI/sh4 were cultured for 6 d before FACS sorting. The GFP+YFP+ cells (BCR-ABL+AHI-1/sh4+) were FACS-sorted after 3 d of expansion. Lin-CD34+ CML cells were prestimulated and transduced with either control or AHI/sh4 virus in a similar manner to that described for CB cells. After 3-4 d of expansion, YFP+CD34+ cells were FACS sorted.
###end p 56
###begin title 57
Cell culture.
###end title 57
###begin p 58
###xml 205 206 205 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 435 436 433 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
FACS-sorted cells were cultured in SFM with or without GFs. At various time points, viable cell numbers were determined by hemocytometer counts of trypan blue-excluding cells. For single cells sorting, YFP+-transduced K562 cells were sorted into the wells of a 96 well plate by FACS. Subsequent clone formation (presence of >/=2 refractile cells) and clone size (total number of refractile cells) in wells seeded with single viable (PI-) cells was assessed by direct visual inspection using an inverted microscope.
###end p 58
###begin title 59
Proliferation assays.
###end title 59
###begin p 60
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 209 210 202 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 314 315 306 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 499 500 491 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Aliquots of 2 x 104 cells were cultured in triplicate in round bottom wells of 96-well Falcon plates in 100 mul media per well. The cells were incubated for 24 and 48 h at 37degreesC. The amount of tritiated [3H]thymidine incorporated during a 4-h pulse of the culture was measured. In brief, 1 muCi of tritiated [3H]thymidine was added to each well. 4 h later, the cells were harvested onto a membrane using a Skatron instruments combi Harvester (LKB Wallace-PerkinElmer). The amount of tritiated [3H]thymidine was measured with a LKB Betaplate scintillation counter.
###end p 60
###begin title 61
Apoptosis analysis.
###end title 61
###begin p 62
###xml 157 158 157 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
The apoptosis analysis was performed using an Apoptosis Detection kit (BD Biosciences) following the manufacturer's instruction. In brief, aliquots of 1 x 105 cells were washed twice with PBS, resuspended in 100 mul binding buffer, and incubated with 5 mul of 7-amino-actinomycin D and 5 mul of PE-conjugated Annexin V antibody at room temperature in the dark for 15 min. 400 mul binding buffer was added for FACS analysis.
###end p 62
###begin title 63
Progenitor assays.
###end title 63
###begin p 64
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">49</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 21 26 <span type="species:ncbi:10090">mouse</span>
###xml 343 348 <span type="species:ncbi:10090">mouse</span>
###xml 487 492 <span type="species:ncbi:9606">human</span>
CFCs and LTC-ICs for mouse BM cells were assayed using culture media from Stem Cell Technologies. Colony counts were performed, using standard scoring criteria, on the basis of the ability to produce colonies containing a minimum of 20 cells after 12 to 14 d of incubation (49). LTCs were set up and maintained using preestablished irradiated mouse marrow LTC feeder layers and weekly half medium changes of LTC medium as previously described (46). CFC assays for transduced K562 cells, human CB cells and CML cells were performed in FCS-containing methylcellulose medium (StemCell Technologies) in the presence or absence of GFs +/- imatinib (0.1-10 muM), dasatinib (10-150 nM), and NL (0.1-10 muM).
###end p 64
###begin title 65
Q-RT-PCR.
###end title 65
###begin p 66
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 394 396 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 487 492 483 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHI-1</italic>
###xml 557 564 553 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 627 632 623 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 834 839 830 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 867 869 863 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
Total RNA was extracted from aliquots of cells using the Absolutely RNA Microprep kit (Stratagene) or TRIzol (Invitrogen), and RT reactions were performed as previously described (46). Real-time PCR was performed using 25 mul of 2X SYBR Green PCR Master Mix (Applied Biosystems), 1 mul of 20 pM of specific primers, 1-2 mul cDNA, and water to a final volume of 50 mul, as previously described (19). Specific forward and reverse primers to detect total expression levels were as follows: AHI-1, 5'-GCCGAGATAGCCCGGTTTATC-3' and 5'-TCAGTTCGGTGAATGTAAACTCC-3'; BCR-ABL, 5'-CATTCCGCTGACCATCAATAAG-3' and 5'-GATGCTACTGGCCGCTGAAG-3'; GAPDH, 5'-CCCATCACCATCTTCCAGGAG-3' and 5'-CTTCTCCATGGTGGTGAAGACG-3'. Optimal conditions for the amplification of these gene products and for normalization of the Ct values of the gene of interest to that of GAPDH were previously described (19).
###end p 66
###begin title 67
Immunoprecipitation and Western blot analyses.
###end title 67
###begin p 68
###xml 49 51 49 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 616 618 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 1351 1353 1317 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 1471 1473 1437 1439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">50</xref>
###xml 1605 1610 <span type="species:ncbi:9606">human</span>
Cells were lysed in PBS as previously described (19). For immunoprecipitation, protein extracts were diluted to approximately1 mug total protein/mul with PBS containing proteinase inhibitors, and specific antibodies were added and incubated at 4degreesC overnight. The immunocomplexes were then captured by protein G bead slurry, rocked, and separated from the beads by washing. The samples were then heated at 70degreesC for 10 min before Western blotting. Protein lysates were then separated on NuPAGE Novex bis-tris gels (Invitrogen), and the filters were probed with specific antibodies as previously described (19). Primary antibodies used in these studies included a monoclonal anti-ABL antibody (8E9; BD Biosciences), an antiphosphotyrosine antibody (4G10; Millipore), anti-phospho-JAK2 (Y1007/Y1008) and anti-JAK2 antibodies (Millipore) in transduced BaF3 cells, anti-phospho-JAK2 (Y1007/Y1008) and anti-JAK2 antibodies (Cell Signaling Technology) in transduced K562 cells, anti-phospho-Src (Tyr 416) and anti-Src antibodies (Cell Signaling Technology), anti-phospho-Akt and anti-Akt antibodies (Cell Signaling Technology), anti-phospho-STAT5 (Tyr694) and anti-STAT5 antibodies (Cell Signaling Technology), anti-phospho-NF-kappaB p65 and anti- NF-kappaB p65 antibodies (Cell Signaling Technology), polyclonal anti-Ahi-1 antibody (C-terminal) (23), C-terminal monoclonal anti-Ahi-1 antibody (C-mAhi-1 M5) generated by a standard procedure as previously described (50), and polyclonal N-terminal AHI-1 antibody, IMX-3395 (IMGENEX). Relative expression levels were normalized to expression levels of human actin (Sigma-Aldrich) after quantification with ImageQuant software. The peptide competition assay was completed as per an online protocol () by Rockland Immunochemicals, Inc.
###end p 68
###begin title 69
Animals.
###end title 69
###begin p 70
###xml 15 18 12 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 169 172 166 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">137</sup>
###xml 446 448 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 786 787 779 780 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 19 23 <span type="species:ncbi:10090">mice</span>
###xml 117 121 <span type="species:ncbi:10090">Mice</span>
###xml 212 216 <span type="species:ncbi:10090">mice</span>
###xml 275 279 <span type="species:ncbi:10090">Mice</span>
###xml 559 563 <span type="species:ncbi:10090">mice</span>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
NOD/SCID-beta2m-/- mice were bred and maintained in microisolator cages and provided with autoclaved food and water. Mice were irradiated at 8-10 wk of age with 350 cGy 137Cs gamma-rays. Cells were injected into mice intravenously a few hours after they had been irradiated. Mice were monitored daily for signs of weight loss or lethargy. Peripheral blood was collected every 1-2 wk, and leukocytes were analyzed by FACS as previously described (46). For tumor formation studies, 10 million cells were injected subcutaneously into the left and right flank of mice, and the mice were monitored daily for the tumor growth. The tumor volume was calculated from the greatest transverse (width) and longitudinal (length) diameter of the tumor using the formula: tumor volume = length x width2/2. All animal experiments were performed in the Animal Resource Centre of BC Cancer Research Centre, and the procedures used were approved by the Animal Care Committee of the University of British Columbia (Vancouver).
###end p 70
###begin title 71
Statistical analysis.
###end title 71
###begin p 72
###xml 146 147 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Results are shown as the mean +/- SEM of values obtained in independent experiments. Differences between groups were assessed using the Student's t test for paired samples.
###end p 72
###begin title 73
Online supplemental material.
###end title 73
###begin p 74
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 106 113 106 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 184 191 184 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</sup>
###xml 212 217 212 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ahi-1</italic>
###xml 222 229 222 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 382 389 382 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR-ABL</italic>
###xml 282 286 <span type="species:ncbi:10090">mice</span>
Fig. S1 shows that overexpression of Ahi-1 confers growth advantage on BaF3 cells and enhances effects of BCR-ABL with increased protein expression and tyrosine phosphorylation of p210BCR-ABL. Fig. S2 shows that Ahi-1 and BCR-ABL-transduced cells purified from BM cells of diseased mice have increased proliferative and antiapoptotic activities and these effects can be enhanced by BCR-ABL. The online supplemental material is available at .
###end p 74
###begin p 75
###xml 189 196 <span type="species:ncbi:9606">patient</span>
The authors thank K. Saw and K. Lambie for excellent technical assistance; Dr. D. Forrest and other members of the Leukemia/Bone Marrow Transplant Program of British Columbia for providing patient samples; the Terry Fox Laboratory FACS Facility for assistance in cell sorting; the Stem Cell Assay Laboratory for cell processing and cryopreservation of normal and CML samples; Novartis for imatinib and NL; Bristol-Myers Squibb for dasatinib; and Dr. C. Eaves for useful discussion.
###end p 75
###begin p 76
This work was supported by grants from the Cancer Research Society and in part by the Leukemia and Lymphoma Society of Canada (X. Jiang). Y. Zhao was a recipient of a Stem Cell Network Fellowship and a Leukemia and Lymphoma Society of Canada Fellowship and A. Ringrose was a recipient of a BC Cancer Studentship. D. DeGeer received a Medical Genetics Graduate Entrance Studentship from University of British Columbia and a BC Cancer Agency Recruitment Training Incentive Studentship. E. Kennah was a recipient of a Medical Genetics Graduate Entrance Studentship from University of British Columbia. X. Jiang is a Michael Smith Foundation for Health Research Scholar.
###end p 76
###begin p 77
The authors have no conflicting financial interests.
###end p 77

